{"id":"surgicel-original","safety":{"commonSideEffects":[{"rate":null,"effect":"Encapsulation of fluid"},{"rate":null,"effect":"Foreign body reaction"},{"rate":null,"effect":"Infection at surgical site"}]},"_chembl":{"chemblId":"CHEMBL5315074","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The product works by converting to a gelatinous mass when it contacts blood, which physically promotes hemostasis and provides a scaffold for clot formation. It is absorbed by the body over 2-4 weeks and is commonly used during surgical procedures to control capillary, venous, and small arterial bleeding when conventional methods are ineffective.","oneSentence":"Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:51.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control)"}]},"trialDetails":[{"nctId":"NCT06664788","phase":"NA","title":"A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery","status":"RECRUITING","sponsor":"Ethicon, Inc.","startDate":"2025-04-16","conditions":"Hemostasis, Hemostatic Techniques","enrollment":108},{"nctId":"NCT05900037","phase":"NA","title":"GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery","status":"COMPLETED","sponsor":"GATT Technologies BV","startDate":"2023-10-02","conditions":"Intraoperative Bleeding, Liver Diseases, Gallbladder Diseases","enrollment":53},{"nctId":"NCT06664775","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery","status":"RECRUITING","sponsor":"Corza Medical GmbH","startDate":"2025-04-02","conditions":"Hemorrhage","enrollment":116},{"nctId":"NCT03783039","phase":"NA","title":"The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)","status":"COMPLETED","sponsor":"Ethicon, LLC","startDate":"2019-01-15","conditions":"Hemorrhage","enrollment":234},{"nctId":"NCT03430609","phase":"NA","title":"Ovarian Function After Use of Various Hemostatic Techniques During Treatment for Endometrioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Faculdade de Ciências Médicas da Santa Casa de São Paulo","startDate":"2018-04-01","conditions":"Endometriosis Ovary, Laparoscopy, Ovary; Functional Disturbance","enrollment":38},{"nctId":"NCT01500135","phase":"PHASE3","title":"Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Bleeding","enrollment":150},{"nctId":"NCT01192022","phase":"PHASE3","title":"TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-08","conditions":"Hemorrhage","enrollment":253},{"nctId":"NCT01637025","phase":"NA","title":"Oxidized Cellulose hEmostAsis evaluatioN","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2012-05","conditions":"Intra-operative Bleeding","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Surgicel® Original","genericName":"Surgicel® Original","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites. Used for Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}